Originally published In Press as doi:10.1074/jbc.M002693200 on May 17, 2000
J. Biol. Chem., Vol. 275, Issue 31, 23456-23461, August 4, 2000
Control of Bisecting GlcNAc Addition to N-Linked
Sugar Chains*
Kazuhiro
Fukuta,
Reiko
Abe,
Tomoko
Yokomatsu,
Fumio
Omae,
Mineko
Asanagi, and
Tadashi
Makino
From the Life Science Laboratory, Mitsui Chemicals, Inc.,
1144 Togo, Mobara, Chiba 297-0017, Japan
Received for publication, March 30, 2000, and in revised form, May 9, 2000
 |
ABSTRACT |
In the present study, experimental control of the
formation of bisecting GlcNAc was investigated, and the
competition between
-1,4-GalT
(UDP-galactose:N-acetylglucosamine
-1,4-galactosyltransferase) and GnT-III
(UDP-N-acetylglucosamine:
-D-mannoside
-1,4-N-acetylglucosaminyltransferase) was
examined. We isolated a
-1,4-GalT-I single knockout human B cell
clone producing monoclonal IgM and several transfectant clones
that overexpressed
-1,4-GalT-I or GnT-III. In the
-1,4-GalT-I-single knockout cells, the extent of bisecting GlcNAc
addition to the sugar chains of IgM was increased, where
-1,4-GalT
activity was reduced to about half that in the parental cells, and
GnT-III activity was unaltered. In the
-1,4-GalT-I transfectants,
the extent of bisecting GlcNAc addition was reduced although GnT-III activity was not altered significantly. In the GnT-III transfectants, the extent of bisecting GlcNAc addition increased along with the increase in levels of GnT-III activity. The extent of bisecting GlcNAc
addition to the sugar chains of IgM was significantly correlated with
the level of intracellular
-1,4-GalT activity relative to that of
GnT-III. These results were interpreted as indicating that
-1,4-GalT
competes with GnT-III for substrate in the cells.
 |
INTRODUCTION |
A
-1,4-linked N-acetylglucosamine residue attached
to the mannose-
-1,4- in the trimannosyl core of N-linked
sugar chains has been described in complex-type and hybrid-type sugar
chains of various glycoproteins such as IgA, IgG, IgM, etc. (1-3).
This GlcNAc residue has been termed a "bisecting" GlcNAc and is
formed by
-D-mannoside
-1,4-N-acetylglucosaminyltransferase
(GnT-III).1 GnT-III is
presumed to be involved in pathological conditions, because an increase
in its expression is accompanied by malignant transformation or
oncofetal changes (4, 5). Although the function of the bisecting GlcNAc
is not well understood, this modification can inhibit the action of
some enzymes (
-mannosidase-II, GnT-II, GnT-V, core
-1,6-fucosyltransferase) in the subsequent biosynthesis of
N-linked sugar chains, suggesting a regulatory role in the
formation of complex-type and hybrid-type sugar chains (6). It is also
known that the occurrence of bisecting GlcNAc-containing sugar chains
on IgG increases with age (7).
Here, we studied a method to control the addition of bisecting GlcNAc
to N-linked sugar chains. We used human monoclonal IgM as a
model glycoprotein for control of the attachment of the bisecting GlcNAc residue. Human IgM is a glycoprotein containing 7-12%
carbohydrate distributed at five N-glycosylation sites in
the constant region of the heavy chain at positions Asn-171, Asn-332,
Asn-395, Asn-402, and Asn-563 (8-12). The sugar chains at Asn-402 and
Asn-563 are high mannose-type chains, and those at Asn-171, Asn-332,
and Asn-395 are complex-type chains. Sugar chains of the human IgM
produced by hybridoma cells were analyzed at each of the five
glycosylation sites on the µ-chain (13, 14). Although the function of
the sugar chains of IgM is not well understood, it has been
demonstrated that the sugar chain structure at Asn-402 on mouse IgM
influences the ability of the IgM-antigen complex to bind complement
(15). Bazin et al. (16) reported that murine
hybridoma-produced IgM lacking the sugar chain at Asn-563 had increased
avidity for antigen. The function of the sugar chains of antibodies has
been well studied in the case of IgG. For example, hypogalactosylation
of IgG has been shown to affect some of the effector functions of
the IgG molecule including binding to complement C1q and
mannose-binding protein (17). Patients with rheumatoid arthritis have a
higher frequency of IgG lacking galactose (18).
Our original interest was to investigate the effect of
hypogalactosylation on the function of IgM. For this purpose, we
attempted to isolate
-1,4-GalT-I-null B cells producing IgM.
Although we failed to isolate
-1,4-GalT-I-null cells, we isolated a
single knockout cell clone in which the
-1,4-GalT level was reduced to half due to disruption of one of the two
-1,4-GalT-I alleles. In
the case of the IgM produced by this
-1,4-GalT-I single knockout clone, hypogalactosylation was not observed; however, we discovered that the extent of bisecting GlcNAc addition to the sugar chains of the
IgM was increased. To explain this unexpected increase in the extent of
bisecting GlcNAc addition, we speculated that
-1,4-GalT might
compete with GnT-III for substrate in the cells. It has been previously
reported that, in an in vitro system using sugar chains in a
free form or glycopeptides, GnT-III and
-1,4-GalT react with an
agalactosyl nonbisected biantennary sugar chain as a common substrate,
suggesting that GnT-III and
-1,4-GalT enzymatically compete for the
substrate in vitro (19, 20) (Fig.
1). However, the occurrence of such
competition in intact cells was viewed as questionable considering the
subcellular localization of the two enzymes, as reported previously
(21-24). In the present study, we attempted to demonstrate
experimentally the competition between
-1,4-GalT and GnT-III in
intact cells. We demonstrate that the extent of bisecting GlcNAc
addition to the sugar chains of IgM is significantly correlated with
the level of intracellular
-1,4-GalT activity relative to that of
GnT-III. Our studies demonstrate that sugar chain structures can be
systematically and quantitatively controlled by regulating the levels
of expression of glycosyltransferases.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Reactions catalyzed by GnT-III
and -1,4-GalT. The addition of galactose
residues is known to inhibit the addition of bisecting GlcNAc in
vitro.
|
|
 |
EXPERIMENTAL PROCEDURES |
Cell Lines--
The experiments were performed using the
following two IgM-producing cell lines. Clone No. 12 is an Epstein-Barr
virus-transformed human lymphoblastoid cell line producing human IgM
against Pseudomonas aeruginosa Homma serotype B, and clone
3-4 is a hybridoma established by fusion of clone No. 12 and an
established human myeloma cell line P109 mutated so as not to produce
IgM µ-chain (25). Hybridoma 3-4 produces the same µ-chain peptide
of IgM as No. 12, and IgM from 3-4 cells reacts with the same serotype
of Pseudomonas aeruginosa as IgM from No. 12 cells.
Cell Culture--
Cells producing human monoclonal IgM were
routinely maintained by static culture at 37 °C (5%
CO2/air) in tissue culture flasks containing NYSF-404
medium (26) and 20% fetal bovine serum (FBS). G418 (800 µg/ml) was
added to cultures of
-1,4-GalT-I or GnT-III transfectant cells.
For IgM production, cells were cultured in flasks (175 cm2)
containing 80 ml of the serum-free medium for 3 days. The supernatant samples were then collected, filtered, and stored at
20 °C.
Isolation of a Cell Line Having Low
-1,4-GalT Activity--
A
human
-1,4-GalT-I gene was isolated from a human leukocyte genomic
library (CLONTECH, catalog number HL1111j) by
plaque hybridization using a probe corresponding to exon 2 of the human
-1,4-GalT-I gene. A
-1,4-GalT-I gene fragment (XhoI
fragment) containing exon 2 and part of introns 1 and 2 was inserted
into the XhoI site of the expression vector pBluescript
II-KS(+) (Stratagene), and its NcoI/XhoI fragment
was deleted. An XhoI/BamHI fragment of pMC1neo
poly(A) (Stratagene) containing a neomycin resistance gene was made
blunt-ended by treatment with mung bean nuclease, followed by addition
of a NotI linker, and the resulting fragment was inserted
into the NotI site of
-1,4-GalT-I exon 2 of the above
vector in order to disrupt the
-1,4-GalT-I gene. A herpes simplex
virus-thymidine kinase coding sequence (PvuII fragment of
pHSV-106, Life Technologies, Inc.) was inserted to the
HincII site of pUC19 (Life Technologies, Inc.), and a
BamHI/HindIII fragment containing the herpes
simplex virus-thymidine kinase sequence from the resulting plasmid was
inserted downstream of the neomycin resistance gene in the targeting
vector. The targeting vector was designated pGEXN-Neo-TK.
No. 12 cells (5 × 106 cells) were suspended in
NYSF-404 medium; then 200 µg of the targeting vector pGEXN-Neo-TK was
added, and the cells were subjected to electroporation (220 V/0.4 cm, 960 microfarads). After standing at room temperature for 10 min, the
cells were transferred to NYSF-404 medium containing 20% FBS and
cultured on plates at an appropriate dilution for 2 days. Then they
were further cultured in NYSF-404 medium containing 800 µg/ml G418
and 20% FBS. After approximately 2 weeks, G418-resistant cells were
selected. The G418-resistant cells were further cultured in NYSF-404
medium containing 2.5 ng/ml ganciclovir (GANC) and 20% FBS, and
GANC-resistant cells were selected.
Homologous recombination was initially detected by PCR using a Neo
primer and a GalT-int primer and next by using an F01 primer and a
GalT-int primer. PCR-positive clones were subjected to Southern blot
analysis to confirm that homologous recombination had occurred. Southern hybridization was carried out according to standard methods (27) using a digoxigenin-labeled DNA probe. The probe (GalT-int probe)
was obtained from genomic DNA by PCR using the primers 5'-GGAGAATCAGATTGATCTAAGAGG-3' and
5'-CGTGGAAGGGATACTGGGGTCCCCTT-3'.
Establishment of Cell Lines Overexpressing
-1,4-GalT or
GnT-III--
The
-1,4-GalT-I expression vector pCXN2-GalT was
constructed by inserting the entire human
-1,4-GalT-I coding region
(28) (EcoRI fragment of pCT7-J20, a kind gift from Dr.
Michiko Fukuda, The Burnham Institute, La Jolla) into the
EcoRI site of the expression vector pCXN2 (29) (a kind gift
from Dr. Jun-ichi Miyazaki, Osaka University, Japan) containing a
neomycin resistance gene, in which a foreign gene is driven by a
-actin promoter. The GnT-III expression vector pCXN2-rGnT-III was
constructed by inserting the entire rat GnT-III coding region
(EcoRI fragment of vector Act-3) (30) (a kind gift from Dr.
Naoyuki Taniguchi, Osaka University, Japan) into the EcoRI
site of the expression vector pCXN2. 100 µg of plasmid DNA and
7.5 × 106 cells were suspended in 0.5 ml of NYSF-404
medium, and the cells were subjected to electroporation (220 V/0.4 cm,
960 microfarads). After standing at room temperature for 10 min, the
cells were transferred to NYSF-404 medium containing 20% FBS and
seeded on plates at an appropriate dilution. Two days later, G418 was
added at 800 µg/ml, and the cells were further cultured. After
approximately 2 weeks, G418-resistant cells were picked up.
Assay of GnT-III and
-1,4-GalT Activities--
Cells (5 × 105) were suspended in 5 µl of buffer (10 mM HEPES buffer, 1% Triton X-100, pH 7.2) and disrupted by
sonication. The lysates were used as the crude enzyme preparations for
the assay of GnT-III and
-1,4-GalT activities.
GnT-III and
-1,4-GalT activities were measured using pyridylaminated
agalactosyl biantennary sugar chain as a substrate as described
in our preceding paper (36). The substrate was prepared as
reported previously (31). The specific activities of GnT-III and
-1,4-GalT were expressed as nanomoles of GlcNAc or galactose transferred per h/106 cells.
Purification of IgM--
IgM was purified by immunoaffinity
chromatography. Cell culture supernatant was loaded onto an
immunoaffinity column (CHROMATOP immobilized anti-human IgM antibody
column, Nihon-gaishi, Japan) equilibrated with phosphate-buffered
saline. After washing with CHROMATOP Wash Buffer A (Nihon-gaishi,
Japan), IgM was eluted with 0.2 M Gly-HCl, pH 2.5. The
eluate was immediately neutralized with 1 M Tris-HCl, pH
8.0, and concentrated and desalted by ultrafiltration using an
Ultrafree 15 centrifugal filter (Millipore).
Release of Sugar Chains from IgM and
Pyridylamination--
Purified IgM was lyophilized and redissolved at
2 mg/ml in 200 mM Tris-HCl buffer, pH 8.2, containing 10 M urea, 150 mM NaCl, and 20 mM
dithiothreitol and incubated at 37 °C for 15 h. Alkylation was
performed by adding 60 mM iodoacetic acid, and the mixture was incubated at 37 °C for 90 min. Thereafter, the solution was dialyzed against 50 mM Tris-HCl buffer containing 2 mM CaCl2, pH 8.2. Enzymatic digestion was then
performed by adding thermolysin (Merck) in an amount corresponding to
1/50 (w/w) of the IgM in the dialyzed sample. After incubation at
37 °C for 15 h, the digest was loaded on a Sephadex G-25
(Amersham Pharmacia Biotech) gel filtration column, and glycopeptide
fractions were collected. The glycopeptides were dissolved in 100 µl
of 100 mM citrate/phosphate buffer, pH 5.0, and digested
with 0.4 milliunits of glycopeptidase A at 37 °C for 15 h. The
digestion products were applied to a Sep-Pak Plus C18 Cartridge
(Waters) pretreated with 10 ml of methanol and 5 ml of water, and then
sugar chains were eluted with 6 ml of 5% acetonitrile in 0.1%
trifluoroacetic acid solution.
The sugar chains obtained were pyridylaminated by the method of Kuraya
and Hase (32). Excess reagents were removed by gel filtration on a
Sephadex G-15 (Amersham Pharmacia Biotech) column (1 × 40 cm)
equilibrated with 10 mM
NH4HCO3.
Structural Analysis of PA-Sugar Chains--
The PA-sugar chains
were first analyzed by anion-exchange HPLC, and the content of sialic
acid was determined. Next, the whole PA-sugar chains were desialylated
with sialidase from Arthrobacter ureafaciens in 0.2 M ammonium acetate buffer, pH 5.0, for 20 h at
37 °C. The desialylated sugar chains were separated as a neutral fraction by anion-exchange HPLC using a Mono Q column (5 × 50 mm,
Amersham Pharmacia Biotech) as described in our preceding paper
(36).
The desialylated PA-sugar chains were analyzed by a two-dimensional
sugar mapping technique (33). First, the desialylated PA-sugar chains
were separated by reversed-phase HPLC on a Shim-pack CLC-ODS column
(6 × 150 mm, Shimadzu, Japan). Each sugar chain fraction was
collected separately and then applied to the second column, TSKgel
Amide-80 (4.6 × 250 mm, Tosoh, Japan). Elution conditions for
these columns were as described by Tomiya et al. (33). Each
PA-sugar chain fraction was sequentially digested with exoglycosidases
to verify the structural identification.
In all HPLC systems, PA-sugar chains were detected on the basis of
fluorescence, and the excitation and emission wavelengths used were 320 and 400 nm, respectively.
Enzymatic digestion of PA-sugar chains was performed with the following
enzymes at 37 °C for 18 h. The PA-sugar chains were incubated
with 20 milliunits of
-fucosidase (bovine kidney) in 20 µl of 0.2 M ammonium acetate buffer, pH 4.5; with 20 milliunits of
-galactosidase (jack bean) in 20 µl of 0.1 M
citrate/phosphate buffer, pH 4.0; or with 20 milliunits of
-N-acetylhexosaminidase (jack bean) in 20 µl of 0.1 M citrate/phosphate buffer, pH 5.0. The reaction mixture
was heated at 100 °C for 3 min to terminate digestion.
 |
RESULTS |
Isolation of a Cell Line Expressing a Low Level of
-1,4-GalT-I
and Structural Analysis of the IgM Sugar Chains--
The targeting
vector pGEXN-Neo-TK (containing a neomycin resistance gene and a herpes
simplex virus-thymidine kinase gene, Fig.
2A) designed for disrupting
the
-1,4-GalT-I allele was introduced into IgM-producing B cell
clone No. 12. At first, 1,100 clones resistant to G418 were selected.
Next, GANC-resistant clones were selected from among the G418-resistant
clones. Among 580 clones resistant to both G418 and GANC, two clones
were shown to be positive for the fragment of the expected length by
PCR using the Neo primer and the GalT-int primer. One of the two
clones, designated Y6-17, was confirmed to be a true disruptant by PCR
using the F01 primer and the GalT-int primer. By Southern blot analysis
using an external probe, it was also confirmed that the expected
homologous recombination had occurred in Y6-17 (Fig. 2B). In
an attempt to isolate a
-1,4-GalT-I double knockout clone, a second
targeting vector was introduced into Y6-17 cells to disrupt the
remaining
-1,4-GalT-I allele in the cells. However, we failed to
obtain such a double knockout clone. Therefore, the single knockout
clone Y6-17 was used as a cell line expressing a low level of
-1,4-GalT in the present study. The level of
-1,4-GalT activity
in the Y6-17 cells was found to be 63% of that in the parental cells
(Table I). The levels of GnT-III activity
and IgM production did not significantly differ comparing the Y6-17
cells and the parental cells.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
Targeted disruption of the
-1,4-GalT-I gene by homologous recombination.
A, targeting strategy. Coding and non-coding exons of
-1,4-GalT-I are indicated by open and hatched
boxes, respectively. The neomycin resistance gene is indicated by
a dotted box. Homologous recombination was detected by PCR
first by using the Neo primer and the GalT-int primer and second by
using the F01 primer and the GalT-int primer. The GalT-int probe shows
the position of the external probe used for Southern blot analysis, and
the expected HindIII/XhoI fragments are
indicated by arrows. B, Southern blot analysis of
targeted cells. Genomic DNA from parental No. 12 cells and targeted
Y6-17 cells were digested with HindIII and XhoI
and hybridized with the GalT-int probe. The expected DNA fragments in
the case of the mutant allele (Mt) and wild-type allele
(Wt) are indicated. kb, kilobase pairs.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
-1,4-GalT and GnT-III activities in parental cells and transfectants
Activity is expressed as nmol of GlcNAc (or Gal) transferred per h per
106 cells. Values are the means ± S.D. of duplicate
assays.
|
|
Sugar chains at five N-glycosylation sites on the IgM
µ-chain were collectively excised and purified from the Y6-17 cells and the parental No. 12 cells. Sugar chain structures were analyzed by
the two-dimensional mapping technique of Tomiya et al. (33) using pyridylaminated (PA-) sugar chains. Reversed-phase HPLC profiles
of desialylated PA-sugar chains derived from each IgM are shown in Fig.
3. The proportion of each type of sugar
chain is shown in Table II. Complex-type
biantennary sugar chains comprised over 50% and high mannose-type
sugar chains comprised about 30% of the total sugar chains of IgM in
both the Y6-17 cells and the parental No. 12 cells. Other types of
sugar chains comprised about 15% of the total, among which each of the
individual types comprised merely 2% or less. Unexpectedly,
biantennary sugar chains with an agalactosyl terminus were not detected
in IgM from the Y6-17 cells that showed reduced levels of
-1,4-GalT
activity as not seen in IgM from the parental cells. On the other hand,
a change in the extent of bisecting GlcNAc addition was observed. The
rate was 62.1% in the IgM from No. 12 cells, whereas it was 73.8% in the IgM from Y6-17 cells. Thus, the extent of bisecting GlcNAc addition
was increased in the case of the
-1,4-GalT-I single knockout
cells.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Reversed-phase HPLC of desialylated PA-sugar
chains derived from IgM produced by parental No. 12 cells and
transfectants. Structures of individual components are shown by
symbols. Structures of high mannose-type sugar chains are
indicated as M5-M9 according to the number of mannose residues.
|
|
Isolation of Clones Overexpressing
-1,4-GalT-I and Structural
Analysis of the IgM Sugar Chains--
The
-1,4-GalT-I expression
vector pCXN2-GalT (containing a neomycin resistance gene) was
introduced into IgM-producing B cells (No. 12). By G418 selection, 170 clones were isolated. The transfectant B12/neo-1 served as a negative
control (vector pCXN2 was introduced). Among the G418-resistant clones,
2 clones designated B12/G-1 and B12/G-2 were chosen as clones
overexpressing
-1,4-GalT-I. The levels of
-1,4-GalT activity in
the B12/G-1 and B12/G-2 cells were 5.7- and 2.7-fold higher,
respectively, than that in the parental No. 12 cells (Table I). The
levels of GnT-III activity and IgM production did not significantly
differ comparing these
-1,4-GalT-I transfectants and the parental
No. 12 cells.
Sugar chains of IgM from the B12/G-1 and B12/G-2 cells were analyzed as
described above (Fig. 3 and Table II). As in the case of IgM from the
parental No. 12 cells, complex-type biantennary sugar chains comprised
over 50% and high mannose-type sugar chains comprised about 15% of
the total sugar chains of IgM in these two
-1,4-GalT transfectants.
The extent of bisecting GlcNAc addition to the biantennary sugar chains
in IgM was 12.7 and 23.9% in the case of the B12/G-1 cells and the
B12/G-2 cells, respectively. The extent in the case of the No. 12 cells
was 62.1% as described above. Thus, the extent of bisecting GlcNAc
addition was reduced in the case of these clones overexpressing
-1,4-GalT-I.
Isolation of Clones Overexpressing GnT-III and Structural Analysis
of the IgM Sugar Chains--
Cells overexpressing GnT-III were
isolated and found to show an increased extent of bisecting GlcNAc
addition, as compared with B cell clone No. 12 and hybridoma clone 3-4 which were used as the parental cell lines. GnT-III activity is
suppressed in the 3-4 clone by the influence of its parent, clone p109,
which displays no GnT-III activity, and the extent of bisecting GlcNAc addition is known to be very low in the 3-4 cells (37). The vector
pCXN2-rGnT-III (containing a neomycin-resistance gene) was introduced
into No. 12 cells and 3-4 cells. By G418 selection, 24 clones and 36 clones were isolated from No. 12 cells transfected with GnT-III and
from 3-4 cells transfected with GnT-III, respectively. The transfectant
clones B12/neo-2 and 3-4/neo served as negative controls (vector pCXN2
was introduced). One of the G418-resistant B cell transfectants,
designated B12/III, showed 16-fold higher GnT-III activity than
parental No. 12 cells (Table I). The levels of
-1,4-GalT activity
and IgM production did not significantly differ comparing the B12/III
cells and the parental No. 12 cells. Three G418-resistant transfectants
derived from clone 3-4 cells, designated 3-4/III-1, 3-4/III-2, and
3-4/III-3, were chosen as clones overexpressing GnT-III. The levels of
GnT-III activity in 3-4/III-1, 3-4/III-2, and 3-4/III-3 cells were
1188-, 727-, and 15-fold higher than that in the parental 3-4 cells,
respectively (Table I). The levels of
-1,4-GalT activity and IgM
production did not significantly differ comparing the three GnT-III
transfectants derived from clone 3-4 and the parental clone 3-4.
The extent of bisecting GlcNAc addition to the biantennary sugar chains
in IgM from B12/III cells was 90.1% (Fig. 3 and Table II), much higher
than that in the case of the parental No. 12 cells (62.1% as described
above). The extent was 4.0% in the case of the hybridoma clone 3-4. With clones 3-4/III-1, 3-4/III-2, and 3-4/III-3, the extents were 94.4, 90.0, and 9.5%, respectively, indicating that the extent of bisecting
GlcNAc addition was increased in the case of these GnT-III
transfectants as compared with the parental 3-4 cells (Fig.
4 and Table
III). It should be noted that the extent
observed in the case of clone 3-4/III-3 reflected a relatively small
increase in GnT-III activity compared with the significant increases
observed in the case of clones 3-4/III-1 and 3-4/III-2.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
Reversed-phase HPLC of desialylated PA-sugar
chains derived from IgM produced by hybridoma 3-4 cells and
transfectants. Structures of individual components are shown as in
Fig. 3.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Structures of desialylated sugar chains derived from IgM produced by
hybridoma 3-4 cells and transfectants
|
|
Relationship between the Extent of Bisecting GlcNAc Addition to
N-Linked Sugar Chains and the Level of Expression of
-1,4-GalT
Relative to That of GnT-III--
The relationship between the extent
of bisecting GlcNAc addition to the biantennary sugar chains of IgM and
the ratio of
-1,4-GalT activity to GnT-III activity in the
IgM-producing cells were examined (Fig.
5). A significant correlation was found
between them.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Relationship between the extent of bisecting
GlcNAc addition and the ratio of -1,4-GalT
activity to GnT-III activity. The extent of bisecting GlcNAc
addition was expressed as the percentage of bisected biantennary chain
in the total of bisected and nonbisected biantennary chains.
|
|
Relationship between the Extent of Sialic Acid Addition and the
Extent of Bisecting GlcNAc Addition--
PA-sugar chains derived from
IgM produced by each cell line were analyzed by anion-exchange HPLC.
The extent of sialic acid addition to the sugar chains was determined
on the basis of their negative charges. PA-sugar chains were
categorized on the basis of their elution positions into one neutral
and two acidic fractions corresponding to asialo, monosialo, and
disialo PA-sugar chains, respectively. The relative proportions of
these are shown in Fig. 6. In the case of
Y6-17, B12/III, 3-4/III-1, and 3-4/III-2 clones, where the extent of
bisecting GlcNAc addition was increased, the proportion of asialo form
was slightly increased, and the average number of sialic acid was
slightly reduced compared with parental clones. On the other hand, in
the case of B12/G-1 and B12/G-2 clones, where the extent of bisecting
GlcNAc addition was reduced, the proportion of disialo form was
slightly increased, and the average number of sialic acid was slightly
increased compared with parental clone, No. 12. Thus, a rough tendency
of the extent of addition of sialic acid residues to be somewhat
diminished by the presence of bisecting GlcNAc residue was
observed.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of sialylation. PA-sugar chains
from each IgM were separated according to the negative charges by
anion-exchange HPLC. The proportions of asialo, monosialo, and disialo
sugar chains were determined on the basis of the peak area. Increase
and decrease of values compared with parental clones are indicated by
arrows.
|
|
 |
DISCUSSION |
We originally attempted to obtain
-1,4-GalT-I-deficient B cells
producing IgM to examine the effect of hypogalactosylation on the
function of IgM. For this purpose, we isolated a single knockout
clone in which the intracellular level of
-1,4-GalT activity was
reduced to half due to disruption of one of the two
-1,4-GalT-I
alleles. In the
-1,4-GalT-I single knockout cells, under-galactosylated sugar chains were not observed in the IgM produced. Instead, we discovered an interesting phenomenon, the extent
of bisecting GlcNAc addition to the sugar chains of IgM was increased
in the cells, suggesting that
-1,4-GalT is somehow involved in the
formation of the bisecting GlcNAc.
It has been shown in vitro that GnT-III and
-1,4-GalT can
react with an agalactosyl nonbisected biantennary sugar chain as a
common substrate (19, 20). When
-1,4-GalT first catalyzes the
conversion of this sugar chain to a galactosylated form, the latter
product can no longer be a substrate for GnT-III, indicating that
GnT-III and
-1,4-GalT compete for an agalactosyl nonbisected biantennary sugar chain as a common substrate. Therefore, the increased
extent of bisecting GlcNAc addition found in the case of
-1,4-GalT-I
single knockout cells could be explained by the competition between
GnT-III and
-1,4-GalT for substrate. Nishiura et al. (34)
also suggested that the extent of bisecting GlcNAc formation and that
of galactose addition in IgG are controlled by the balance between
GnT-III activity and
-1,4-GalT activity. For such competition to
occur, however, GnT-III and
-1,4-GalT should be located at the same
subcellular site. It is well known that glycosyltransferases are
located on the specific lumenal side of the Golgi apparatus in the
order of the oligosaccharide processing pathway.
-1,4-GalT is known
to be localized on the trans Golgi stacks (21, 22), whereas GnT-III is
considered to be present on the medial Golgi stacks (23, 24). That is to say, the two enzymes were considered to be located at different sites. Therefore, it has been thought that
-1,4-GalT would not likely be able to compete with GnT-III in intact cells, even if the two
enzymes compete in vitro when together they are allowed to
react with an agalactosyl nonbisected biantennary sugar chain.
In the present study, we examined whether
-1,4-GalT and GnT-III
compete for a common substrate within the cells. As described above, the extent of bisecting GlcNAc addition to the sugar chains of
IgM was increased in the case of
-1,4-GalT-I single knockout clone
Y6-17, whereas the extent was decreased in the case of the
-1,4-GalT-I transfectants. In the GnT-III transfectants, the extent
increased along with the increase in levels of GnT-III activity. The
extent of bisecting GlcNAc addition to the sugar chains of IgM was
significantly correlated with the level of intracellular
-1,4-GalT
activity relative to that of GnT-III. From these findings, the
competition between the two enzymes in cells is apparent. Therefore, it
was concluded that the addition of the bisecting GlcNAc residue was not
only catalyzed by GnT-III but was also controlled by the level of
expression of
-1,4-GalT relative to that of GnT-III. Thus, we have
demonstrated that the extent of bisecting GlcNAc addition to sugar
chains can be controlled by changing the levels of expression of the
competing enzymes,
-1,4-GalT and GnT-III. The demonstrated
competition between
-1,4-GalT and GnT-III means that these two
enzymes co-exist at the same site in the cells. However, since we still
do not know where the overexpressed
-1,4-GalT-I and GnT-III proteins
are localized on the Golgi stacks in the transfectants, further study
is needed to confirm completely the competition between these two
enzymes in the cells.
It is noted that a rough tendency of addition of sialic acid residues
to be somewhat suppressed by the presence of bisecting GlcNAc residue
was observed. This result might indicate that the presence of the
bisecting GlcNAc residue inhibits sialyltransferase reaction as
reported in vitro (35).
A functional difference between IgM molecules with and without the
bisecting GlcNAc has not been clearly demonstrated so far in our
studies on the pharmacokinetics and binding to C1q (data not shown).
The functional role of the bisecting GlcNAc residues added to the sugar
chains of IgM should be elucidated through further investigation.
It is well known that sugar chains play important roles in defining the
characteristics of glycoproteins such as their biological activity,
immunogenicity, pharmacokinetics, solubility, and protease resistance.
The functions of glycoproteins are expected to be improved by
remodeling of the sugar chain structures. Techniques for controlling
the sugar chain structures are necessary for this purpose. Here we have
succeeded in controlling sugar chain structures systematically for the
first time by regulating the levels of expression of
glycosyltransferases, even though the control was performed only in
terms of the attachment of bisecting GlcNAc. The present work should
serve as a cornerstone for further studies aimed to control sugar chain structures.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Akira Kobata and Dr. Tamao Endo
(Tokyo Metropolitan Institute of Gerontology, Japan) for their helpful
comments. We are also grateful to Dr. Naoyuki Taniguchi (Osaka
University, Japan) for providing rat GnT-III cDNA and to Dr.
Michiko N. Fukuda (The Burnham Institute, La Jolla) for providing human
-1,4-GalT-I cDNA. We also thank Dr. Jun-ichi Miyazaki (Osaka
University, Japan) for providing vector pCXN2.
 |
FOOTNOTES |
*
This work was supported by the New Energy and Industrial
Technology Development Organization (NEDO) as a part of the Research and Development Projects of the Industrial Science and Technology Frontier Program in Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Life Science
Laboratory, Mitsui Chemicals, Inc., 1144 Togo, Mobara, Chiba 297-0017, Japan. Tel.: 81-475-25-6727; Fax: 81-475-25-6553.
Published, JBC Papers in Press, May 17, 2000, DOI 10.1074/jbc.M002693200
 |
ABBREVIATIONS |
The abbreviations used are:
GnT-III, UDP-N-acetylglucosamine:
-D-mannoside
-1,4-N-acetylglucosaminyltransferase;
-1, 4-GalT,
UDP-galactose:N-acetylglucosamine
-1,4-galactosyltransferase;
PA, pyridylamino-;
FBS, fetal bovine
serum;
PCR, polymerase chain reaction;
HPLC, high performance liquid
chromatography;
GANC, ganciclovir.
 |
REFERENCES |
| 1.
|
Baenziger, J.,
and Kornfeld, S.
(1974)
J. Biol. Chem.
249,
7260-7269
|
| 2.
|
Mizuochi, T.,
Taniguchi, T.,
Shimizu, A.,
and Kobata, A.
(1982)
J. Immunol.
129,
2016-2020
|
| 3.
|
Cahour, A.,
Debeire, P.,
Hartmann, L.,
Montreuil, J.,
van Halbeek, H.,
and Vliegenthart, J. F. G.
(1984)
FEBS Lett.
170,
343-349
|
| 4.
|
Miyoshi, E.,
Nishikawa, A.,
Ihara, Y.,
Gu, J.,
Sugiyama, T.,
Hayashi, N.,
Fusamoto, H.,
Kamada, T.,
and Taniguchi, N.
(1993)
Cancer Res.
53,
3899-3902
|
| 5.
|
Yoshimura, M.,
Nishikawa, A.,
Ihara, Y.,
Nishiura, T.,
Nakao, H.,
Kanayama, Y.,
Matuzawa, Y.,
and Taniguchi, N.
(1995)
Int. J. Cancer
60,
443-449
|
| 6.
|
Schachter, H.
(1986)
Biochem. Cell Biol.
64,
163-181
|
| 7.
|
Yamada, E.,
Tsukamoto, Y.,
Sasaki, R.,
Yagyu, K.,
and Takahashi, N.
(1997)
Glycoconj. J.
14,
401-405
|
| 8.
|
Shimizu, A.,
Putnam, F. W.,
Paul, C.,
Clamp, J. R.,
and Johnson, I.
(1971)
Nat. New Biol.
231,
73-76
|
| 9.
|
Putnam, F. W.,
Florent, G.,
Paul, C.,
Shinoda, T.,
and Shimizu, A.
(1973)
Science
182,
287-291
|
| 10.
|
Ohbayashi, H.,
Endo, T.,
Mihaesco, E.,
Gonzales, M. G.,
Kochibe, N.,
and Kobata, A.
(1989)
Arch. Biochem. Biophys.
269,
463-475
|
| 11.
|
Hickman, S.,
Kornfeld, R.,
Osterland, C. K.,
and Kornfeld, S.
(1972)
J. Biol. Chem.
247,
2156-2163
|
| 12.
|
Chapman, A.,
and Kornfeld, R.
(1979)
J. Biol. Chem.
254,
816-823
|
| 13.
|
Monica, T. J.,
Williams, S. B.,
Goochee, C. F.,
and Maiorella, B. L.
(1995)
Glycobiology
5,
175-185
|
| 14.
|
Leibiger, H.,
Kersten, B.,
Albersheim, P.,
and Darvill, A.
(1998)
Glycobiology
8,
497-507
|
| 15.
|
Wright, J. F.,
Shulman, M. J.,
Isenman, D. E.,
and Painter, R. H.
(1990)
J. Biol. Chem.
265,
10506-10513
|
| 16.
|
Bazin, R.,
Darveau, A.,
Martel, F.,
Pelletier, A.,
Piche, L.,
St-Laurent, M.,
Thibault, L.,
Demers, A.,
Boyer, L.,
Lemieux, G.,
and Lemieux, R.
(1992)
J. Immunol.
149,
3889-3893
|
| 17.
|
Tsuchiya, N.,
Endo, T.,
Matsuta, K.,
Yoshinoya, S.,
Aikawa, T.,
Kosuge, E.,
Takeuchi, F.,
Miyamoto, T.,
and Kobata, A.
(1989)
J. Rheumatol.
16,
285-290
|
| 18.
|
Parekh, R. B.,
Roitt, I. M.,
Isenberg, D. A.,
Dwek, R. A,
Ansell, B. M.,
and Rademacher, T. W.
(1988)
Lancet
1,
966-969
|
| 19.
|
Fujii, S.,
Nishiura, T.,
Nishikawa, A.,
Miura, R.,
and Taniguchi, N.
(1990)
J. Biol. Chem.
265,
6009-6018
|
| 20.
|
Gleeson, P. A.,
and Schachter, H.
(1983)
J. Biol. Chem.
258,
6162-6173
|
| 21.
|
Roth, J.,
and Berger, E. G.
(1982)
J. Cell Biol.
92,
223-229
|
| 22.
|
Goldberg, D. E.,
and Kornfeld, S.
(1983)
J. Biol. Chem.
258,
3159-3165
|
| 23.
|
Nagai, K.,
Ihara, Y.,
Wada, Y.,
and Taniguchi, N.
(1997)
Glycobiology
7,
769-776
|
| 24.
|
Ihara, Y.,
Senda, T.,
Nishikawa, A.,
Miyoshi, E.,
Yoshimura, M.,
Zhang, N.-Z.,
and Taniguchi, N.
(1995)
Glycoconj. J.
12,
447
|
| 25.
|
O'Oka, H.,
Chonan, E.,
Mizutani, K.,
Fukuda, T.,
Kuroiwa, Y.,
Ono, Y.,
and Shigeta, S.
(1992)
Microbiol. Immunol.
36,
1305-1316
|
| 26.
|
Yabe, N.,
Matsuya, Y.,
Yamane, I.,
and Takada, M.
(1986)
In Vitro Cell. & Dev. Biol.
22,
363-368
|
| 27.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 28.
|
Aoki, D.,
Appert, H. E.,
Johnson, D.,
Wong, S. S.,
and Fukuda, M. N.
(1990)
EMBO J.
9,
3171-3178
|
| 29.
|
Niwa, H.,
Yamamura, K.,
and Miyazaki, J.
(1991)
Gene (Amst.)
108,
193-199
|
| 30.
|
Yoshimura, M.,
Nishikawa, A.,
Ihara, Y.,
Taniguchi, S.,
and Taniguchi, N.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8754-8758
|
| 31.
|
Tokugawa, K.,
Oguri, S.,
and Takeuchi, M.
(1996)
Glycoconj. J.
13,
53-56
|
| 32.
|
Kuraya, N.,
and Hase, S.
(1992)
J. Biochem. (Tokyo)
112,
122-126
|
| 33.
|
Tomiya, N.,
Awaya, J.,
Kurono, M.,
Endo, S.,
Arata, Y.,
and Takahashi, N.
(1988)
Anal. Biochem.
171,
73-90
|
| 34.
|
Nishiura, T.,
Fujii, S.,
Kanayama, Y.,
Nishikawa, A.,
Tomiyama, Y.,
Iida, M.,
Karasuno, T.,
Nakao, H.,
Yonezawa, T.,
Taniguchi, N.,
and Tarui, S.
(1990)
Cancer Res.
50,
5345-5350
|
| 35.
|
Nemansky, M.,
Schiphorst, W. E. C. M.,
and Van den Eijnden, D. H.
(1995)
FEBS Lett.
363,
280-284
|
| 36.
|
Fukuta, K.,
Abe, R.,
Yokomatsu, T.,
Kono, N.,
Asanagi, M.,
Omae, F.,
Minowa, M. T.,
Takeuchi, M.,
and Makino, T.
(2000)
Glycobiology
10,
421-430
|
| 37.
|
Fukuta, K.,
Abe, R.,
Yokomatsu, T.,
Kono, N.,
Nagatomi, Y.,
Asanagi, M.,
Shimazaki, Y.,
and Makino, T.
(2000)
Arch. Biochem. Biophys.
378,
142-150
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Klisch, E. Jeanrond, P.-C. Pang, A. Pich, G. Schuler, V. Dantzer, M. P Kowalewski, and A. Dell
A Tetraantennary Glycan with Bisecting N-Acetylglucosamine and the Sda Antigen is the Predominant N-Glycan on Bovine Pregnancy-Associated Glycoproteins
Glycobiology,
January 1, 2008;
18(1):
42 - 52.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.